title: Chronic graft-versus-host disease presenting as eosinophilic fasciitis: therapeutic challenges and an additional case.
abstract: Chronic graft-versus-host disease (cGVHD) is one of the main late complications of allogeneic hematopoietic stem cell transplant and a major contributor to the mortality and morbidity in surviving recipients. Skin is the most common involved organ in cGVHD and may mimic a wide spectrum of dermatological conditions in its clinical and histopathologic manifestations. Some of the commonly simulated diseases are scleroderma, morphea, and lichen sclerosus. Chronic GVHD simulating eosinophilic fasciitis (EF) is relatively rare, frequently presenting with skin induration, a typical "peau d'orange" appearance, peripheral blood eosinophilia, myalgia, arthralgia, and arthritis leading to joint contractures in severe cases.Diagnosis is based on clinical manifestations and histopathology. Treatment is challenging because most cases are refractory to first-line therapy of glucocorticoids and calcineurin inhibitors (CNIs), and there is no standard second-line therapy.We report a comprehensive review of literature on all reported cases of CGVHD presenting as EF. We also describe an additional interesting case of cGVHD presenting as EF that was resistant to traditional therapy of high-dose glucocorticoids and cyclosporin A, but showed complete resolution of skin manifestations after addition of imatinib.Chronic GVHD presenting as EF is a rare variant of sclerodermatous cGVHD. Diagnosis is difficult, and treatment of cGVHD mimicking EF remains a therapeutic challenge because of obscure pathogenesis and poor response to traditional immunosuppressive medications. Emerging insights into the pathogenesis of cGVHD have resulted in the development of novel targeted therapies, which may improve outcomes and should be attempted in this subset of the disease. Larger studies are warranted to substantiate these preliminary findings.
authors.affiliation: From the *Wooster Family Health Center, Wooster; †Orthopedic and Rheumatologic Institute; ‡Hematology and Oncology, Cleveland Clinic Main Campus, Cleveland, OH; and §Rheumatology Sutter Medical Group, Sutter Medical Foundation, Sacramento, CA.
authors.forename: Chitra Clive
authors.initials: CC
authors.lastname: Ganta
authors.forename: Soumya
authors.initials: S
authors.lastname: Chatterjee
authors.forename: Brad
authors.initials: B
authors.lastname: Pohlman
authors.forename: Mehrnaz
authors.initials: M
authors.lastname: Hojjati
mesh_terms: D000328:Adult; D002908:Chronic Disease; D004802:Eosinophilia / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D005208:Fasciitis / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male